| Literature DB >> 29296363 |
Alessia Pica1,2, Sarah Abbeel1, Nicolas Von der Weid3, Ali Sajadi4, Laura Negretti2, Franziska Phan-Hug5, Michael Hauschild5, Daniel Schmidhalter6, Valerie Schwitzgebel7, Damien Weber8.
Abstract
We assessed the efficacy and the toxicity for pediatric craniopharyngioma patients of fractionated stereotactic radiotherapy (FSRT). Between May 2000 and May 2009, 9 patients (male to female ratio, 5:4) with craniopharyngiomas underwent FSRT (median dose, 54 Gy). Among the 9 patients, 6 received radiation therapy (RT) for recurrent tumors and 3 for residual disease as adjuvant therapy after incomplete surgery. Median tumor volume was 2.3 cm3 (range, 0.1-5.8). The median target coverage was 93.7% (range 79.3-99.8%). The median conformity index was 0.94 (range, 0.6-1.4). Dose to the hippocampal region was assessed for all patients.After a median follow-up of 62.5 months (range, 32-127)the treated volume decreased in size in four of eight patients (50%). One patient was lost to follow-up. Local control and survival rates at 3 years were 100% and there were no marginal relapses. One patient, with a chronic bilateral papillary oedema after surgery, visual defect deteriorated after FSRT to a complete hemianopsia. One male patient with normal pituitary function before FSRT presented with precocious puberty at the age of 7.4 years, 24 months after FSRT. Four patients (50%) were severely obese at their last visit. FSRT is a safe treatment option for craniopharyngioma after incomplete resection.Entities:
Keywords: Craniopharyngioma; Fractionated stereotactic radiotherapy; Tumor Control; Visual Complications
Year: 2013 PMID: 29296363 PMCID: PMC5658812
Source DB: PubMed Journal: J Radiosurg SBRT